Open AccessPrognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy
Author(s) -
Shogo Nakamoto,
Masahiko Ikeda,
Shinichiro Kubo,
Mari Yamamoto,
Tetsumasa Yamashita,
Chihiro Kuwahara
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10066
Subject(s) - sorafenib , medicine , hazard ratio , thyroid cancer , oncology , confidence interval , adverse effect , gastroenterology , cancer , hepatocellular carcinoma
We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC).